ADC Therapeutics SA (ADCT) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts ADCT Hot Sheet
Join SI Premium – FREE
ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.73), $0.07 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $17.29 million versus the consensus estimate of $31.22 million.
For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 1st Source (SRCE) PT Raised to $92 at KBW After a 'High Quality Result'
- Sierra Bancorp (BSRR) Tops Q3 EPS by 27c
- Kaiser Aluminum Corporation (KALU) PT Lowered to $127 at KeyBanc
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
